Pembrolizumab for Early Triple-Negative Breast Cancer

At first interim analysis (n=602 previously untreated stage II/III triple-negative breast cancer), significantly more patients on pembrolizumab plus neoadjuvant chemotherapy had pathological complete response vs. placebo plus neoadjuvant chemotherapy (64.8% vs. 51.2%; p<0.001).

Source:

New England Journal of Medicine